Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19

PURPOSE: End-organ damage in coronavirus disease-2019 (COVID-19) is linked to “cytokine storm” and excessive release of inflammatory mediators. Various novel therapies have been used in COVID-19 including urinary trypsin inhibitor therapy. This study explores the efficacy of ulinastatin in COVID-19....

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Ashish, Kasliwal, Rajeev, Jain, Srishti Suresh, Jain, Rohit, Gupta, Divyansh, Gupta, Priyamvada, Jain, Anand, Tambi, Rohan, Panwar, Puneet, Meena, Munesh, Jain, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237140/
https://www.ncbi.nlm.nih.gov/pubmed/35836625
http://dx.doi.org/10.5005/jp-journals-10071-24156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237140/
https://www.ncbi.nlm.nih.gov/pubmed/35836625
http://dx.doi.org/10.5005/jp-journals-10071-24156

Ejemplares similares